Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ConocoPhillips
COP
|
+$3.16B |
| 2 |
Merck
MRK
|
+$2.72B |
| 3 |
SLB Ltd
SLB
|
+$1.62B |
| 4 |
Target
TGT
|
+$1.6B |
| 5 |
General Mills
GIS
|
+$930M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$2.81B |
| 2 |
Blackrock
BLK
|
+$2.57B |
| 3 |
US Bancorp
USB
|
+$1.84B |
| 4 |
M&T Bank
MTB
|
+$808M |
| 5 |
Huntington Bancshares
HBAN
|
+$595M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.45% |
| 2 | Financials | 11.9% |
| 3 | Healthcare | 10.6% |
| 4 | Consumer Discretionary | 9.01% |
| 5 | Industrials | 8.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SBT
3226
DELISTED
Sterling Bancorp, Inc. Common Stock
SBT
| $270K | ﹤0.01% |
55,854
+55
| +0.1% | +$260 |
|
3227
Stereotaxis
STXS
$138M
| $270K | ﹤0.01% |
153,321
+284
| +0.2% | +$605 |
|
3228
Twin Disc
TWIN
$343M
| $269K | ﹤0.01% |
35,531
+3,796
| +12% | +$36.9K |
|
3229
Strawberry Fields REIT
STRW
$191M
| $269K | ﹤0.01% |
22,553
+6,435
| +40% | +$74.4K |
|
3230
PLAYSTUDIOS Inc
MYPS
$95.1M
| $264K | ﹤0.01% |
208,131
-40,501
| -16% | -$65.9K |
|
3231
Solid Biosciences
SLDB
$859M
| $254K | ﹤0.01% |
68,607
+5,220
| +8% | +$22.3K |
|
3232
Biote Corp
BTMD
$68.5M
| $252K | ﹤0.01% |
75,738
| – | – |
|
|
TPIC
3233
DELISTED
TPI Composites
TPIC
| $250K | ﹤0.01% |
310,436
-300,933
| -49% | -$393K |
|
|
GRFS
3234
Grifois
GRFS
$5.4B
| $244K | ﹤0.01% |
34,302
+1,102
| +3% | +$8.31K |
|
3235
Geospace Technologies
GEOS
$95.1M
| $240K | ﹤0.01% |
33,321
| – | – |
|
3236
Achieve Life Sciences
ACHV
$684M
| $239K | ﹤0.01% |
89,562
| – | – |
|
3237
On Holding
ONON
$12.7B
| $233K | ﹤0.01% |
+5,296
| New | +$278K |
|
|
PAMT
3238
PAMT Corp
PAMT
$301M
| $231K | ﹤0.01% |
19,009
+2,255
| +13% | +$32.5K |
|
3239
Paymentus
PAY
$5.03B
| $228K | ﹤0.01% |
8,752
| – | – |
|
3240
Lineage Cell Therapeutics
LCTX
$284M
| $227K | ﹤0.01% |
503,193
+86,970
| +21% | +$51K |
|
3241
Acrivon Therapeutics
ACRV
$70.2M
| $226K | ﹤0.01% |
111,320
-2,520
| -2% | -$13.6K |
|
3242
Cabaletta Bio
CABA
$442M
| $221K | ﹤0.01% |
159,866
+50,606
| +46% | +$108K |
|
3243
Northern Technologies International Corp
NTIC
$80.5M
| $220K | ﹤0.01% |
21,176
| – | – |
|
3244
AirSculpt Technologies
AIRS
$349M
| $219K | ﹤0.01% |
93,909
-6,762
| -7% | -$30.4K |
|
3245
XBiotech
XBIT
$68.9M
| $218K | ﹤0.01% |
67,355
+8,918
| +15% | +$30.7K |
|
|
MPX
3246
DELISTED
Marine Products Corp
MPX
| $216K | ﹤0.01% |
25,788
+1,959
| +8% | +$17.2K |
|
3247
Consumer Portfolio Services
CPSS
$199M
| $216K | ﹤0.01% |
24,927
| – | – |
|
3248
Larimar Therapeutics
LRMR
$426M
| $216K | ﹤0.01% |
100,457
-24,670
| -20% | -$78K |
|
|
ADVM
3249
DELISTED
Adverum Biotechnologies
ADVM
| $214K | ﹤0.01% |
49,024
-10,710
| -18% | -$48.3K |
|
|
GRVY
3250
GRAVITY
GRVY
$432M
| $212K | ﹤0.01% |
+3,501
| New | +$209K |
|
Similar funds
Charles Schwab's Q1 2025 Portfolio in Review
As of Q1 2025, Charles Schwab held 3,548 positions worth $533B, down 1.7% from $542B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2025: portfolio turnover was 3.6%. Charles Schwab opened 55 new positions and exited 74, leaving the 3,548-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 24% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2025 buy was iShares Currency Hedged MSCI Eurozone ETF: 7,259,426 shares worth $283M.
- Charles Schwab added most to ConocoPhillips in Q1 2025, an estimated $3.16B increase.
- Charles Schwab's biggest Q1 2025 reduction was Pfizer, cutting an estimated $2.81B.
- Charles Schwab fully exited Brookfield in Q1 2025, selling an estimated $218M.
- Charles Schwab's ten largest holdings make up 20% of its $533B portfolio in Q1 2025.
- Charles Schwab opened 55 new positions and closed 74 in Q1 2025.
- Charles Schwab's portfolio value fell 1.7% quarter-over-quarter to $533B.
Based on Charles Schwab's 13F filing for Q1 2025, filed 9 May 2025.